<DOC>
	<DOCNO>NCT02976116</DOCNO>
	<brief_summary>Fruquintinib combination Gefitinib first-line therapy patient advance non-squamous non-small-cell lung cancer harbor activate EGFR mutation : single-arm , multicenter , phase II study</brief_summary>
	<brief_title>A Phase II Study Fruquintinib Combination With Gefitinib Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This phase II trial evaluate combination fruquintinib gefitinib advance NSCLC . The endpoint evaluate efficacy safety combination .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Signed Informed Consent Form . Age 18 75 year old . Histologically cytological document stage IIIB/IV nonsquamous nonsmall cell lung cancer patient never receive systematic treatment latestage disease . ECOG 01 Patients must measurable lesion Prior systematic treatment advance NSCLC Absolute neutrophil count ( ANC ) &lt; 1.5×109 /L , platelet count &lt; 100 ×109/L , hemoglobin &lt; 9 g/dL Total bilirubin &gt; 1 ULN ; SGOT ( AST ) , SGPT ( ALT ) , &gt; 1.5 ULN ; patient liver metastasis，AST ALT &gt; 3 ULN Known HIV positive Hypersensitivity either investigation drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Fruquintinib</keyword>
	<keyword>NSCLC</keyword>
	<keyword>1st line</keyword>
</DOC>